NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative ...

Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications The provisional patent application describes novel nanoparticle ...

TUCSON, Ariz., March 2, 2026 /PRNewswire/ -- Keys Inc. today announced the filing of U.S. Provisional Patent Application No. 63/939,152 with the United States Patent and Trademark Office (USPTO) ...

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (RAPH), a clinical-stage biotechnology company developing an innovative research platform based on cannabinoids free of THC and ...

Actinium Pharmaceuticals, Inc. has announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) pertaining to Iomab-B, the Company's ...

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH) , a clinical-stage biotechnology company developing an innovative ...

“Refiling a provisional is just a bad idea when you can, for a few hundred dollars more, keep hold of that earliest priority date and continue on the path to obtaining a patent.” The question that we ...

Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd.

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 05, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement issued by Sarborg Limited (“Sarborg”) ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. You have a great idea for an invention, and you think it is ...